Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival

Clinical Cancer Research

Volumn 3, Issue 4, 1997, Pages 605-611

  Singhai, Hemant ^a   Bautista, Diosdado S ^a   Tonkin, Katia S ^a   O'Malley, Frances P ^a   Tuck, Alan B ^a   Chambers, Ann F ^a   Harris, John F ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPONTIN;

ADULT; ARTICLE; BREAST CANCER; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SURVIVAL;

ADULT; BREAST NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MENOPAUSE; MIDDLE AGED; NEOPLASM METASTASIS; OSTEOPONTIN; PHOSPHOPROTEINS; POSTMENOPAUSE; REFERENCE VALUES; REGRESSION ANALYSIS; SIALOGLYCOPROTEINS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0030988805     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Denhardt D. T., and Guo X. Osteopontin: a protein with diverse functions. FASEB J., 7: 1475-1482, 1993.
2. Giachelli, C. M., Schwartz, S. M., and Liaw, L. Molecular and cellular biology of osteopontin: potential role in cardiovascular disease. Trends Cardiovasc. Med., 5: 88-95, 1995.
3. Patarca, R., Saavedra, R. A., and Cantor, H. Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte activation-1/osteopontin gene. Crit. Rev. Immunol., 13: 225-246, 1993.
4. Denhardt, D. T., Butler, W. T., Chambers, A. F., and Senger, D. R. (eds.). Osteopontin. Role in Cell Signalling and Adhesion. Ann. NY Acad. Sci., 760: 1-388, 1995.
5. Senger, D. R., Perruzzi, C. A., and Papadopoulos, A. Elevated expression of secreted phosphoprotein 1 (osteopontin, 2ar) as a consequence of neoplastic transformation. Anticancer Res., 9: 1291-1299, 1989.
6. Brown, L. F., Papadopoulos-Sergiou, A., Berse, B., Manseau, E. J., Tognazzi, E., Perruzzi, C. A., Dvorak, H. F., and Senger, D. R. Os- teopontin expression and distribution in human carcinomas. Am. J. Pathol., 145: 610-623, 1994.
7. Bellahcene, A., and Castronovo, V. Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am. J. Pathol., 146: 95-100, 1995.
8. Hirota, S., Ito, A., Nagoshi, J., Takeda, M., Kurata, A., Takatsuka, Y., Kohri, K., Nomura, S., and Kitamura, Y. Expression of bone matrix protein messenger ribonucleic acids in human breast cancers. Possible involvement of osteopontin in development of calcifying foci. Lab Invest., 72: 64-69, 1995.
9. Senger, D. R., Perruzzi, C. A., Gracey, C. R., Papadopoulos, A., and Tenen, D. G. Secreted phosphoproteins associated with neoplastic transformation: close homology with plasma proteins cleaved during blood coagulation. Cancer Res., 48: 5770-5774, 1988.
10. Shiraga, H., Min, W., VanDusen, W. J., Clayman, M. D., Miner, D., Terrell, C. H., Sherbotie, J. R., Foreman, J. W., Przysiecki, C., Nielson, E. G., and Hoyer, J. R. Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily. Proc. Natl. Acad. Sci. USA, 89: 426-430, 1992.
11. Worcester, E. M., Blumenthal, S. S., Beshensky, A. M., and Lewand, D. L. The calcium oxalate crystal growth inhibitor protein produced by mouse kidney cortical cells in culture is osteopontin. J. Bone Miner. Res., 7: 1029-1036, 1992.
12. Bautista, D. S., Denstedt, J., Chambers, A. F., and Harris, J. F. Low molecular weight variants of osteopontin generated by serine proteinases in urine of patients with kidney stones. J. Cell. Biochem., 61: 402-409, 1996.
13. Lopez, C. A., Olson, E. S., Adams, J. C., Mou, K., Denhardt, D. T., and Davis, R. L. Osteopontin expression detected in adult cochleae and inner ear fluids. Hear Res., 85: 210-222, 1995.
14. Bautista, D. S., Xuan, J. W., Hota, C., Chambers, A. F., and Harris, J. F. Inhibition of Arg-Gly-Asp (RGD)-mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin. J. Biol. Chem., 269: 23280-23285, 1994.
15. Bautista, D. S., Saad, Z., Chambers, A. F., Tonkin, K. S., O'Malley, F. P., Singhal, H., Tokmakejian, S., Bramwell, V., and Harris, J. F. Quantification of osteopontin in human plasma with an ELISA: basal levels in pre- and postmenopausal women. Clin. Biochem., 29: 231-239, 1996.
16. Xuan, J. W., Hota, C., and Chambers, A. F. Recombinant GST-human osteopontin fusion protein is functional in RGD-dependent cell adhesion. J. Cell. Biochem., 54: 247-255, 1994.
17. Ruslin, G. J. S., Crawford, M., Lambert, J., Ledermann, J., Coleman, R., and Meely, K. Trial of oral hexalen for relapsed ovarian carcinoma: comparison of CA125 and BORTC response definitions. Proc. Am. Soc. Clin. Oncol., 14: 269, 1995.
18. Saksela, E. Prognostic markers in epithelial ovarian cancer. Int. J. Gynecol. Pathol., 12: 156-161, 1993.
19. Sevelda, P., Schemper, M., and Spona, J. CA 125 as an independent prognostic factor for survival in patients with epithelial cancer. Am. J. Obstet. Gynecol., 161: 1213-1216, 1989.
20. Bartlett, N. L., Freiha, F. S., and Torti, F. M. Serum markers in germ cell neoplasms. Hematol.-Oncol. Clin. N. Am., 5: 1245-1260, 1991.
21. Stamey, T. A., Yang, N., Hay, A. R., McNeal, J. E., Freina, F. S., and Redwine, E. Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med., 317: 909-916, 1987.
22. Minton, J. P., Hoehn, J. L., Gerber, D. M., Horsley, J. S., Connolly, D. P., Salwan, F., Fletcher, W. S., Cruz, A. B. Jr., Gatchell, F. G., Oviedo, M., Meyer, K. K., Leffall, L. D., Jr., Berk, R. S., Stewart, P. A., and Kurucz, S. E. Results of a 400-patient carcinoembryonic antigen second-look colorectal cancer study. Cancer (Phila.), 55: 1284-1290, 1985.
23. Nicolini, A., Colombini, C., Luciani, L., Carpi, A., and Giuliani, L. Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients. Br. J. Cancer, 64: 154-158, 1991.
24. Pirolo, F., Pacini, P., Borsotti, M., la Morgia, R., Mungai, R., Cappellini, M., Cardona, G., Cataliotti, L., Marzano, S., Neri, B., Distante, V., and Berti, P. The role of CA 15-3 and MCA monoclonal antibody assays in the detection of primary and recurrent breast cancer. Anticancer Res., 11: 729-731, 1991.
25. Gion, M., Plebani, M., Mione, R., Penzo, C., Meo, S., and Burlina, A. Serum CA549 in primary breast cancer: comparison with CA15.3 and MCA. Br. J. Cancer, 69: 721-725, 1994.
26. de Wit, R., Hock, F. J., Bakker, P. J., and Veenhof, C. H. A comparison of CA-549 with CA 15-3 and MCA in patients (PTS) with metastatic breast cancer (meeting abstract). Proc. Annu. Meet Am. Soc. Clin. Oncol., 10: A13, 1991.
27. Schlageter, M. H., Toubert, M. E., Guil, M., Espie, M., and Najean, Y. CA549: a new tumor marker in breast carcinoma. J. Tumor Marker Oncol., 6: 43, 1991.
28. Correale, M., Abbate, I., Dragone, C. D., Tedone, T., Gargano, G., Catino, A., Paradiso, A., Addabbo, L., Musci, M. D., and De Lena, M. Serum and cytosolic levels of CA549 in breast cancer patients. Clin. Exp. Obstet. Gynecol., 20: 264-267, 1993.
29. Chan, D. W., Beveridge, R. A., Bhargava, A., Wilcox, P. M., Kennedy, M. J., and Schwartz, M. K. Breast cancer marker Ca549: a multicenter study. Am. J. Clin. Pathol., 101: 465-470, 1994.
30. Dominguez, G. L., Martin, C. L. M., Crespo, A., and Avila, C. MCA serum determination in breast carcinoma patients for the diagnosis of bone metastases. Int. J. Biol. Markers, 8: 203-207, 1993.
31. Tondini, C., Hayes, D. F., Gelman, R., Henderson, I. C., and Kufe, D. W. Comparison of CA15-3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res., 48: 4107-4112, 1988.
32. Yamashita, J., Ogawa, M., Yamashita, S., Nomura, K., Kuramoto, M., Saishoji, T., and Shin, S. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res., 54: 1630-1633, 1995.
33. Behrend, E. I., Craig, A. M., Wilson, S. M., Denhardt, D. T., and Chambers, A. F. Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Res., 54: 832-837, 1994.
34. Gardner, H. A. R., Berse, B., and Senger, D. R. Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts. Oncogene, 9: 2321-2326, 1994.
35. Su, L., Mukherjee, A. B., and Mukherjee, B. B. Expression of antisense osteopontin RNA inhibits tumor promoter-induced neoplastic transformation of JB6 epidermal cells. Oncogene, 10: 2163-2169, 1995.
36. Denhardt, D. T., and Chambers, A. F. Overcoming obstacles to metastasis. Defenses against host defenses: osteopontin (OPN) as a shield against attack by cytotoxic host cells. J. Cell. Biochem., 56: 48-51, 1994.